Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-121 in Children and Adolescents With Hyperchylomicronemia
NCT07371767Phase 1Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- CRISPR-Cas9, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of CS-121 in primary chylomicronemia (FCS) (3 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoints: Dose-limiting toxicities at 14 days and Treatment-emergent adverse events at 10 months. Started Jan 2026; status: recruiting.
02
Drugs
CS-121
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on NCT07371767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371767.